Strategic partnerships Candela recently formed collaborations with Mitra Bio and Verde Group in 2026, signaling opportunities for co-development, research-backed efficacy studies, and joint go-to-market initiatives that sales teams can leverage to expand into new clinical segments and geographies.

Product portfolio expansion The launch of the Glacē System at IMCAS 2026 along with demonstrations of Matrix RF skin renewal and Vbeam Pro vascular treatment positions Candela to upsell existing customers with new platforms and cross-sell complementary devices to aesthetic practices seeking comprehensive solutions.

Award and visibility Recognition as Best Skin Product/Range of the Year at The Aesthetics Awards 2026 enhances brand credibility and can be used to justify premium pricing, accelerate tender opportunities, and open doors with larger clinics and hospital-affiliated aesthetics programs.

Education and V&I Candela Institute for Excellence supports ongoing research and education partnerships; sales teams can channel these programs to secure site visits, CME-style trainings, and physician advocacy, driving adoption and loyalty among high-volume practices.

Global growth indicators With a global leadership stance, a US-based headquarters, and a revenue range of 100–250 million, Candela sits between mid-market and upper-mid-market peers, offering scalable solutions for growing practices seeking dependable energy-based devices and a trusted supplier relationship.